Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Lenus Biosciences Spac
AddedFeb 17, 2024
UpdatedJun 18, 2026
Lenus Biosciences Spac

Lenus Biosciences Spac

Public

Lenus Bioscience, a medical cannabis SPAC, focuses on acquiring innovative pharmaceutical companies for synergistic growth and market impact.

HQ
Dallas, TX, US
Founded
2019
Overview
Compare
Fundraising
Employees

Lenus Biosciences Spac is dedicated to acquiring and consolidating companies in the medical cannabis sector, emphasizing R&D, pharmaceutical production, and distribution. They aim to create synergies and introduce new technologies through strategic acquisitions, ultimately positioning themselves for a successful IPO.

Key achievements include the development of drug nanospheres and advancements in medical cannabis applications. Their strategic approach has attracted significant interest, positioning Lenus Biosciences as a notable player in the biotech and pharmaceutical industries.

Lenus Biosciences Spac - Similar Companies

Skye Bioscience logo

Skye Bioscience

Hemp Synergistics logo

Hemp Synergistics

Platinum Biosciences logo

Platinum Biosciences

Sporos Bioventures logo

Sporos Bioventures

Next Frontier Biosciences logo

Next Frontier Biosciences

NantBio logo

NantBio

Lumen Bioscience logo

Lumen Bioscience

Franklin Group logo

Franklin Group

Nalu Bio logo

Nalu Bio

nalubio.com

THC Farmaceuticals logo

THC Farmaceuticals

toke.city

Diverse Biotech logo

Diverse Biotech

Life Science Holding Company logo

Life Science Holding Company

Outlier Biopharma logo

Outlier Biopharma

Arcana Biotech Holdings logo

Arcana Biotech Holdings

Harvest Direct Enterprises logo

Harvest Direct Enterprises

Lenus Biosciences Spac - Quick Facts

Who are Lenus Biosciences Spac's competitors?

Companies similar to Lenus Biosciences Spac include Skye Bioscience, Hemp Synergistics, Platinum Biosciences and Sporos Bioventures.

When was Lenus Biosciences Spac founded?

Lenus Biosciences Spac was founded in 2019.

Where is Lenus Biosciences Spac's headquarters located?

Lenus Biosciences Spac's headquarters is located in Dallas, TX, US.

When was Lenus Biosciences Spac's last funding round?

Lenus Biosciences Spac's most recent funding round was for $4.5M (USD) in November 2019.

How much has Lenus Biosciences Spac raised to-date?

As of Nov 11, 2019, Lenus Biosciences Spac has raised a total of $4.5M (USD).

How many employees does Lenus Biosciences Spac have?

Lenus Biosciences Spac has 5 employees as of Feb 4, 2024.

Lenus Biosciences Spac - Classification

Ownership
  • Public
Technology
  • Biotech
Customer
  • Enterprise
Main Product
  • Pharmaceuticals
Tags
  • Financial
  • SPAC
NAICS
  • 459900Other Miscellaneous Retailers
  • 459990All Other Miscellaneous Retailers
  • 459991Tobacco, Electronic Cigarette, and Other Smoking Supplies Retailers
  • 450000Retail Trade
  • 459000Sporting Goods, Hobby, Musical Instrument, Book, and Miscellaneous Retailers
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
Show 1 more industry code
NAICS
  • 620000Health Care and Social Assistance